NEXGEL, Inc.

NXGL

US65344E1073

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Companyâs converting and packaging business, which is based in Granbury, Texas. All of its gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty.

Sector

Pharmaceuticals

Calendar

2024-06-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for NEXGEL, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.197 USD

Average target price

6 USD

Spread / Average Target

+173.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEXGEL, INC.	+5.40%	13.68M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-13 EDT			5-day change	1st Jan Change
2.245 ^USD	+2.18%		+2.05%	+5.40%

05-13	Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $1.3M, vs. Street Est of $1.2M	MT
04-01	NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $1.3M, vs. Street Est of $1.2M	05-13	MT
NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024	04-01
Earnings Flash (NXGL) NEXGEL Posts Q4 Revenue $1.1M	04-01	MT
NEXGEL, Inc. Provides Revenue Guidance for the First Quarter of 2023	04-01	CI
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024	01-16	CI
Top Premarket Decliners	01-16	MT
Nexgel Subsidiary, Cg Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024	01-09	CI
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors	12-12	CI
Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America	12-11	MT
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America	12-11	CI
NEXGEL, Inc. acquired Kenkoderm from Olympus Trading Company, LLC for $1.1 million.	12-04	CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.	11-13	CI
NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Transcript : NEXGEL, Inc., Q3 2023 Earnings Call, Nov 13, 2023	11-13
Earnings Flash (NXGL) NEXGEL Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M	11-13	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-10-30	MT
NEXGEL Unit Executes Supply Agreement with AbbVie	23-10-30	MT
NEXGEL, Inc. Secures Supply Agreement with AbbVie Inc	23-10-30	CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.	23-08-14	CI
NEXGEL, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : NEXGEL, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Earnings Flash (NXGL) NEXGEL Reports Q2 Revenue $1.2M, vs. Street Est of $1M	23-08-14	MT
NEXGEL Partners With Enigma Health for Retail Distribution, Marketing Services in North America	23-07-19	MT
Transcript : NEXGEL, Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15